Addex TherapeuticsADXN
13F holders, Q3 2024 (September 30)3holders +1
1new positions
0sold out
$9.77avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Addex Therapeutics Ltd. (ADXN) in their 13F filings, up 1 from Q2 2024. 1 opened new positions and 0 sold out. The largest holders were ADAR1 Capital Management, LLC ($10K), Morgan Stanley ($3K) and Rhumbline Advisers ($337).
- Company
- Addex Therapeutics Ltd.
- CUSIP
- 00654J206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $337 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 135 shares bought and 1,147 shares sold, net −1,012 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| ADAR1 Capital Management, LLC | 0.00% | Add +11.1% | 1,000 | $10K |
| Morgan Stanley | 0.00% | Reduce -76.5% | 353 | $3K |
| Rhumbline Advisers | 0.00% | New | 35 | $337 |
"% of holder's portfolio" is ADXN's weight in each manager's 13F, not the share of Addex Therapeutics Ltd. the manager owns.